ERBB2 and colorectal neoplasm: Antibodies (i.e., trastuzumab, pertuzumab), tyrosine kinase inhibitors (TKIs; i.e., lapatinib, neratinib, tucatinib), antibody drug conjugates (ADCs) like ado-trastuzumab emtansine (T-DM1) and T-DXd, and HER2-targeting immunotherapy are among the current therapeutic agents targeting HER2 in HER2-positive colorectal tumors (Fig. 2) [20, 47–49].